Neuro20 Sparks Hope for Long COVID Recovery

Neuro20 Technologies Corp. has released a white paper detailing improvements in patients with Long COVID. This includes progress in fatigue, mobility, and neurological symptoms. The company’s FDA-cleared device activates 44 muscles through pre-designed sequences.

Since April 2024, seven patients used the device with notable results. Two patients, initially using walkers, improved significantly after a single treatment.

The FDA and Medicare-approved device targets muscle performance, circulation, range of motion, and muscle spasms. It’s prescribed for both clinical and home use.

Long COVID impacts around 24 million Americans and 65 million people globally, costing the economy an estimated $3.7 trillion. Neuro20 advocates for randomized controlled trials to further study the device’s efficacy.